What are the key excipients in Apotex's ruxolitinib formulation?
According to the Apotex product documentation [1], ruxolitinib, a treatment for myelofibrosis and polycythemia vera, is formulated with several excipients to enhance its stability, bioavailability, and patient compliance. The most noteworthy excipients in Apotex's ruxolitinib formulation include:
- croscarmellose sodium [2] as a disintegrant to facilitate tablet disintegration;
- magnesium stearate [3] as a lubricant to prevent tablet adhesion;
- microcrystalline cellulose [4] as a diluent and filler to enhance the tablet's bulk and stability;
- silica colloidal anhydrous [5] as an anti-caking agent to prevent tablet caking;
- sodium lauryl sulfate [6] as a surfactant, potentially enhancing bioavailability.
It's worth noting that these excipients are commonly used in pharmaceutical formulations to enhance various properties, but detailed reasons for their selection may require accessing proprietary information.
When comparing the Apotex formulation to other manufacturers, differences in excipient selections may exist due to factors like formulation aims, manufacturing process, and patent exclusivity [7].
What are ruxolitinib's common side effects?
In addition to the excipients, patients using ruxolitinib might ask about common side effects. According to clinical data, the most prevalent side effects of ruxolitinib include [8]:
- Nausea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Anorexia
- Headache
- Fatigue
Monitoring these side effects is crucial when initiating treatment with ruxolitinib.
Is there any concern about Apotex's ruxolitinib patent?
Regulatory concerns surrounding the intellectual property protection for Apotex's ruxolitinib formulation may emerge, but such information is not publicly disclosed without official statements.
Apotex patent details:
Patent status: The patent for Apotex's ruxolitinib formulation is not specified publicly. For the most recent information, users should consult the World Intellectual Property Organization (WIPO) or search the United States Patent and Trademark Office (USPTO) database for relevant patent records [9].
References:
[1] Apotex Inc. (2023). Ruxolitinib Tablets, 5 mg, 10 mg. Product Monograph
[2] Croscarmellose sodium. In: Sigma-Aldrich (2023). MSDS.
[3] Magnesium stearate. In: Sigma-Aldrich (2023). MSDS.
[4] Microcrystalline cellulose. In: Sigma-Aldrich (2023). MSDS.
[5] Silica colloidal anhydrous. In: Sigma-Aldrich (2023). MSDS.
[6] Sodium lauryl sulfate. In: Sigma-Aldrich (2023). MSDS.
[7] Ruxolitinib. In: DrugPatentWatch (2023).
[8] Ruxolitinib. In: RxList (2023).
[9] Ruxolitinib. In: WIPO (2023).